Advertisement
UK markets close in 3 hours 35 minutes

  • FTSE 100

    8,088.82
    +44.01 (+0.55%)
     

  • FTSE 250

    19,806.25
    +6.53 (+0.03%)
     

  • AIM

    754.93
    +0.06 (+0.01%)
     

  • GBP/EUR

    1.1633
    +0.0005 (+0.04%)
     

  • GBP/USD

    1.2431
    -0.0022 (-0.18%)
     

  • Bitcoin GBP

    53,479.63
    +350.22 (+0.66%)
     

  • CMC Crypto 200

    1,437.89
    +13.79 (+0.97%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CRUDE OIL

    83.03
    -0.33 (-0.40%)
     

  • GOLD FUTURES

    2,329.30
    -12.80 (-0.55%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,198.39
    +60.74 (+0.33%)
     

  • CAC 40

    8,137.73
    +31.95 (+0.39%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

AstraZeneca boosted by good results for biotech asthma drug

Reuters - UK Focus

LONDON, May 17 (Reuters) - AstraZeneca (NYSE: AZN - news) 's drive to rebuild its portfolio of new medicines received a boost on Tuesday with positive results for a biotech drug for severe asthma that the company has previously flagged as a potential $2 billion-a-year product.

The antibody treatment benralizumab, which will compete against rivals including GlaxoSmithKline (Other OTC: GLAXF - news) 's recently launched Nucala, was well tolerated and succeeded in reducing asthma attacks in two pivotal late-stage clinical trials.

AstraZeneca said it planned to submit the product for regulatory approval in the United States and Europe in the second half of 2016.

(Reporting by Ben Hirschler; editing by Jason Neely)